Newsinc24 Team 
A drug to treat coronavirus patients, developed by the DRDO (Defence Research and Development Organisation), has been approved for emergency use by the Drugs Controller General of India (DCGI). The drug comes in powder form in a sachet and is taken orally by dissolving it in water. A DRDO lab and Hyderabad-based Dr Reddy's Laboratories developed the anti-Covid therapeutic application of the drug 2-deoxy-D-glucose (2-DG)."Clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid patients," DRDO said in an official statement on Saturday.
In April last year, during the first wave of Covid the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), had conducted laboratory experiments with the help of Centre for Cellular and Molecular Biology (CCMB), Hyderabad and found that this molecule works effectively against SARS-CoV-2 virus and inhibits the viral growth. Clinical trial was conducted at 11 hospitals all over the country. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country, the DRDO said.
Related Items
DRDO successfully tests indigenous UAV missile in dual combat modes
NCB makes first-ever seizure of ‘Jihadi Drug’ Captagon
DRDO & IAF successfully conduct maiden trial of indigenous TARA glide weapon